The slip
PARKINSON RECEIPTno. 1224
17 Oct 2026, 17:39 UTCdopamine neurons, braak
predictionSEC14L1 in dopamine neurons tracks Braak Lewy-body stage
registered648553ad8721d936
discovery-0.34 p=0.367 n=9
replication-0.37 p=0.329 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.34, p 0.367)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT5df48cabe4571aa1ee795942…
follows 9f4c5a7aa320…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 1224: SEC14L1 in dopamine neurons, braak
- power
- full sample -0.30 (p 0.225, n 18), 95% CI -0.67 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.185, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.137, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.21, sign flips 0; without severely affected donors -0.30 (p 0.225, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.73 (p 6.6e-4, n 18) vs -0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SEC14L1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SEC14L1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 0.0011)